Becker's Healthcare December 7, 2023
Out of the hundreds of new drugs entering the U.S. market, eight made tailwinds in the healthcare industry, according to GoodRx.
Note: This list does not include notable FDA approvals in December.
1. Paxlovid (nirmatrelvir/ritonavir) for COVID-19: In late May, the COVID-19 antiviral treatment gained FDA approval after being on the market since December 2021 with an emergency use authorization. It’s the first-choice treatment option for nonhospitalized patients 12 and older, according to the National Institutes of Health.
2. Arexvy, Abrysvo and Beyfortus for respiratory syncytial virus: Before 2023, the only drug approved for RSV was Synagis (palivizumab), which is only indicated for high-risk patients. Arexvy (RSVPreF3) is the first FDA-approved RSV vaccine, and RSV vaccine Abrysvo (RSVpreF)...
Today's Sponsors
Today's Sponsor